An open label, multi-center, non-interventional post-marketing surveillance to monitor the safety and efficacy of ALTARGO (retapamulin) administered in Korean patients according to the prescribing information

Category Primary study
JournalAnnals of Dermatology
Year 2018
This article has no abstract
Epistemonikos ID: 20d6b39a54ae2239f280a1726aaa57243d24ab26
First added on: Feb 09, 2025